Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $556,300.80 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 10,560 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80. Following the sale, the chief executive officer directly owned 80,360 shares in the company, valued at approximately $4,233,364.80. This trade represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $50.76 on Friday. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $56.30. The stock’s 50-day simple moving average is $47.57 and its 200 day simple moving average is $42.79. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 22.56, a price-to-earnings-growth ratio of 0.78 and a beta of 0.74.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.9%. Phibro Animal Health’s payout ratio is currently 21.33%.

Wall Street Analyst Weigh In

PAHC has been the subject of several analyst reports. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Phibro Animal Health by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares in the last quarter. State Street Corp raised its position in shares of Phibro Animal Health by 5.4% during the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after buying an additional 48,243 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after acquiring an additional 626,492 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Phibro Animal Health by 1.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock worth $18,394,000 after acquiring an additional 6,826 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.